Thus, we propose that GCS inhibition constitutes a potential target for protecting neurons from ADDL-mediated neurotoxicity and insulin resistance in Alzheimer’s disease. This evidence concerns the gene ADD3 and early-onset autosomal dominant Alzheimer disease.